ADAPTIMMUNE
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
ADAPTIMMUNE
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2008-01-01
Address:
Oxton, York, United Kingdom
Country:
United Kingdom
Website Url:
http://www.adaptimmune.com
Total Employee:
501+
Status:
Active
Contact:
+1 (215) 825 9260
Total Funding:
499.5 M USD
Technology used in webpage:
Domain Not Resolving IPv6 ReCAPTCHA Nginx ReCAPTCHA V2 DoubleClick.Net Microsoft Google Adsense Mobile Optimized New Relic
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Kuros Biosciences
Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Theravectys
Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.
Current Advisors List
Board_member
2014-09-01
Board_member
Current Employees Featured
Gavin Wood Chief Financial Officer @ Adaptimmune
Chief Financial Officer
2020-04-01
William (Bill) Bertrand Chief Operating Officer @ Adaptimmune
Chief Operating Officer
Ian Laing Founder & Non-Executive Director @ Adaptimmune
Founder & Non-Executive Director
2008-12-01
Helen Tayton-Martin Chief Business Officer @ Adaptimmune
Chief Business Officer
2008-07-01
Adrian (Ad) Rawcliffe Chief Executive Officer @ Adaptimmune
Chief Executive Officer
Cintia Piccina Chief Commercial Officer @ Adaptimmune
Chief Commercial Officer
2024-01-01
Dennis Williams TitleSr. Vice President, Late Stage Development @ Adaptimmune
TitleSr. Vice President, Late Stage Development
2019-12-01
John Lunger Chief Patient Supply Officer @ Adaptimmune
Chief Patient Supply Officer
James Noble Founder & CEO @ Adaptimmune
Founder & CEO
2008-07-01
Elliot Norry Senior Vice President & Chief Medical Officer @ Adaptimmune
Senior Vice President & Chief Medical Officer
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-03-06 | TCR2 | TCR2 acquired by Adaptimmune | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Adaptimmune
Genentech
Genentech investment in Post-IPO Equity - Adaptimmune
Eight Roads Ventures
Eight Roads Ventures investment in Venture Round - Adaptimmune
Merlin Nexus
Merlin Nexus investment in Series A - Adaptimmune
F-Prime Capital
F-Prime Capital investment in Series A - Adaptimmune
Wellington Management
Wellington Management investment in Series A - Adaptimmune
Ridgeback Capital
Ridgeback Capital investment in Series A - Adaptimmune
University of Oxford
University of Oxford investment in Series A - Adaptimmune
Foresite Capital
Foresite Capital investment in Series A - Adaptimmune
Novo Holdings
Novo Holdings investment in Series A - Adaptimmune
Key Employee Changes
Official Site Inspections
http://www.adaptimmune.com Semrush global rank: 1.47 M Semrush visits lastest month: 16.99 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
Adaptimmune.com lookup results from whois.tucows.com server:
- Domain created: 24th-Apr-2008
- Domain updated: 24th-Jul-2024
- Domain expires: 24th-Apr-2026 1 Year, 8 Days left
- Website age: 16 Years, 355 Days
- Registrar Domain ID: 1457107306_DOMAIN_COM-VRSN
- Registrar Url: http://www.tucows.com
- Registrar WHOIS Server: whois.tucows.com
- Registrar Abuse Contact Email: domainabuse@tucows.com
- Registrar Abuse Contact Phone: +1.4165350123
- Name server:
- NS0.ADAPTIMMUNE.COM
- NS1.ADAPTIMMUNE.COM
- NS2.ADAPTIMMUNE.COM
- NS3.ADAPTIMMUNE.COM
- NS4.ADAPTIMMUNE.COM
More informations about "Adaptimmune"
Adaptimmune - Wikipedia
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University …See details»
Leadership Team :: Adaptimmune (ADAP)
In this role, she built the Allogeneic Research organization from the ground up and took the concept of iPSC-derived allogeneic T-cell therapies from an idea into the potential for an allogeneic candidate in the clinic. Prior to her SVP …See details»
Our Company :: Adaptimmune (ADAP)
Adaptimmune embraces this personalized approach from discovery through delivery with fully integrated capabilities including research, global clinical development, translational sciences, commercialization, and manufacturing.See details»
Adaptimmune - Crunchbase Company Profile & Funding
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor …See details»
Adaptimmune - The Org
Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment Industries Biotechnology , EducationSee details»
Adaptimmune - Company Profile - Tracxn
Dec 7, 2024 What are the most recent funding rounds of Adaptimmune? Its latest funding round was a Series A round on Sep 24, 2014 for $104M. 12 investors participated in its latest round, …See details»
Adaptimmune Information - RocketReach
Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities …See details»
Adaptimmune - Funding, Financials, Valuation & Investors
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. Search Crunchbase. Start Free Trial . Chrome Extension. ... Which types …See details»
Member profile: Adaptimmune Ltd | BIA - bioindustry.org
Adaptimmune, a leader in cell therapy, is a late-stage biopharmaceutical company, with a pipeline of therapies in clinical trials in 10 solid tumors. About Adaptimmune Ltd Adaptimmune, a …See details»
Company Information - Adaptimmune (ADAP)
Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer. We believe our …See details»
Adaptimmune Company Profile: Overview and Full News Analysis
Adaptimmune is reducing its headcount by 33% and targeting approximately $300 million in aggregate cost savings over the next four years . As part of this restructuring, the Company …See details»
Adaptimmune Company Profile - Office Locations, Competitors
Oct 29, 2024 Adaptimmune has 4 employees across 4 locations and $60.28 m in annual revenue in FY 2023. See insights on Adaptimmune including office locations, competitors, …See details»
US FDA approves Adaptimmune's therapy for rare type of cancer
Aug 2, 2024 The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind treatment for a rare type of cancer in the soft tissues that most …See details»
Investor Relations :: Adaptimmune (ADAP)
Nov 18, 2024 Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the body’s own machinery – the T …See details»
Adaptimmune to File for Lete-Cel FDA Approval Following Cuts …
2 days ago Adaptimmune estimates that 400 new sarcoma patients per year are currently eligible for Tecelra, and that closer to 1,000 new sarcoma patients per year would be eligible …See details»
Adaptimmune Assist
AdaptimmuneAssist includes: ‐ Connection with a Treatment Navigator ‐ Travel and financial support programs for eligible patients ‐ Access to the AdaptimmuneAssist Order PortalSee details»
Our Leaders :: Adaptimmune (ADAP)
Prior to her SVP role, Dr. Brewer held a series of senior managerial roles within Adaptimmune’s research organization. Her experience in immunotherapy and cell therapy at Adaptimmune …See details»
AGC Biologics to Support Adaptimmune’s Solid Tumor Cell Therapy
17 hours ago AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a development and manufacturing …See details»
Corporate Presentations :: Adaptimmune (ADAP)
4 days ago Latest Corporate Deck. Jan 13, 2025. Adaptimmune Corporate Deck January 2025See details»
Adaptimmune Announces U.S. FDA Breakthrough Therapy …
3 days ago Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine …See details»